Spotlight On: Humira® (Adalimumab) / Amjevita™ (Adalimumab-Atto) / Cyltezo® (Adalimumab-Adbm) / Hyrimoz™ (Adalimumab-Adaz) / Hadlima™ (Adalimumab-Bwwd) / Abrilada™ (Adalimumab-Afzb) / Hulio® (Adalimumab-Fkjp) / Yusimry™ (Adalimumab-Aqvh) / Idacio® (Adalimumab-Aacf) / Yuflyma® (Adalimumab-Aaty) / Simlandi® (Adalimumab-Ryvk) - May 2026

Why It Matters

Accurate claim counting shapes the perceived strength of adalimumab’s patent estate, influencing biosimilar entry strategies and investor valuations in the lucrative rheumatoid‑arthritis market.

Key Takeaways

• Adalimumab patents face numerous IPRs and infringement lawsuits.
• Claims counted per case; duplicates across proceedings increase total count.
• IPR 2017‑00826/01008 and 2017‑00827/01009 merged as single reviews.
• Methodology influences valuation of Humira biosimilar patent portfolios.
• PDF provides detailed claim breakdown for legal and market analysis.

Pulse Analysis

Humira (adalimumab) remains a cornerstone therapy for autoimmune diseases, generating over $20 billion in annual global sales. Its market dominance has spurred a wave of biosimilar entrants—Amjevita, Cyltezo, Hyrimoz, and others—each vying for a slice of the lucrative rheumatoid‑arthritis and Crohn’s disease segments. As patents expire, the competitive landscape hinges less on clinical differentiation and more on the strength and enforceability of the underlying patent portfolio, making legal analytics a critical business tool.

The May 2026 Venable LLP report sheds light on how claim counts are compiled across Inter‑Partes Reviews (IPRs) and infringement lawsuits. By counting each claim once per proceeding but allowing duplicates across separate cases, the total number of contested claims can appear larger than the unique claim set. Notably, IPRs 2017‑00826/01008 and 2017‑00827/01009 are treated as single reviews, simplifying the tally. This methodological nuance directly impacts assessments of patent robustness, influencing settlement negotiations, licensing fees, and the timing of biosimilar launches.

For pharmaceutical companies and investors, understanding this claim‑counting framework is essential for risk modeling and valuation. An inflated claim count may suggest a more formidable barrier to entry, potentially deterring biosimilar developers or inflating royalty expectations. Conversely, clear insight into the actual claim landscape can uncover opportunities for strategic challenges or design‑around pathways. As the adalimumab market evolves, stakeholders who leverage detailed legal analytics will be better positioned to navigate patent litigation and capture value in the post‑patent era.